Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics, Inc (ELTX)
:ELTX
Holding ELTX?
Track your performance easily
ELTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.96 - $11.45
Previous CloseN/A
Volume37.28K
Average Volume (3M)27.23K
Market Cap
$69.50M
Enterprise Value$67.04M
Total Cash (Recent Filing)$1.40M
Total Debt (Recent Filing)$5.32M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 28, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding10,791,326
10 Day Avg. Volume33,914
30 Day Avg. Volume27,233
Standard Deviation0.26
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$9.00Price Target Upside48.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Elicio Therapeutics News
PremiumCompany Announcements
Elicio Therapeutics Advances ELI-002 and Secures Funding
PremiumCompany Announcements
Elicio Therapeutics Appoints Robert Connelly as Financial OfficerOwnership Overview
19.52% Insiders
2.98% Mutual Funds
0.13% Other Institutional Investors
74.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.96 and its highest was $11.45 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $69.50M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Mar 28, 2025 which is in 66 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on Nov 13, 2024. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.66.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate is -0.88.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 10,791,326 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 4.808%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
---
Elicio Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (48.27% Upside)
$9.00 (48.27% Upside)
Insider Transactions
Bought Shares
Worth $500.0 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.88%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.
---
ELTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(48.27% Upside)
Technical Analysis
Advaxis
―
Cellectar Biosciences
―
RAPT Therapeutics
―
Revolution Medicines
―
CytomX Therapeutics
―
Best Analysts Covering ELTX
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-8.83%
reiterated a buy rating 5 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.83% per trade.
---